UF Innovate | Accelerate resident client NeXtGen Biologics has announced the issuance of its third U.S. patent, part of a broader portfolio of U.S. and international patents focused on extracellular matrix components derived from a highly regenerative, non-mammalian species known as the axolotl, a type of urodele amphibian. In addition to their previous patents, the most recent patent is directed to a tissue culture system that provides patent coverage for two conditioned media and ECM, and methods of use of these products.
Read more about NeXtGen Biologics Announces Issuance of a Third New Patent Covering Axolotl-Derived Technology.
